AR041745A1 - Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos - Google Patents

Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos

Info

Publication number
AR041745A1
AR041745A1 ARP030104008A ARP030104008A AR041745A1 AR 041745 A1 AR041745 A1 AR 041745A1 AR P030104008 A ARP030104008 A AR P030104008A AR P030104008 A ARP030104008 A AR P030104008A AR 041745 A1 AR041745 A1 AR 041745A1
Authority
AR
Argentina
Prior art keywords
drug formulation
dosage form
dosage
formulation
hydrophobic
Prior art date
Application number
ARP030104008A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR041745A1 publication Critical patent/AR041745A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Una formulación del fármaco y una forma de dosificación. La formulación del fármaco cumple la función de incrementar la biodisponibilidad de los fármacos hidrófobos administrados al tracto gastrointestinal ("tracto GI") de un sujeto determinado. La formulación del fármaco de la presente se formula como una nanosuspensión auto-emulsionable, que forma una emulsión in situ al introducirse en un medio acuoso. La forma de dosificación, puede formarse utilizando varios materiales diferentes y puede configurarse para administrar la formulación del fármaco al tracto GI de un sujeto utilizando cualquier mecanismo adecuado. Se puede crear una forma de liberación de dosificación controlada para administrar la formulación del fármaco a una velocidad apropiada durante un período de tiempo adecuado. Si se la crea como una forma de dosificación de liberación controlada, puede ser una forma de dosificación osmótica.
ARP030104008A 2002-10-31 2003-10-31 Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos AR041745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42318402P 2002-10-31 2002-10-31

Publications (1)

Publication Number Publication Date
AR041745A1 true AR041745A1 (es) 2005-05-26

Family

ID=32312618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104008A AR041745A1 (es) 2002-10-31 2003-10-31 Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos

Country Status (11)

Country Link
US (1) US20040142040A1 (es)
EP (1) EP1556000A1 (es)
JP (1) JP2006507309A (es)
KR (1) KR20050083875A (es)
CN (1) CN1728982A (es)
AR (1) AR041745A1 (es)
AU (1) AU2003291667A1 (es)
CA (1) CA2504031A1 (es)
TW (1) TW200423968A (es)
UY (1) UY28057A1 (es)
WO (1) WO2004041246A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
AU2003230885A1 (en) * 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US20060047025A1 (en) * 2004-06-29 2006-03-02 Matthew Piazza Viscous materials and method for producing
KR20070043894A (ko) * 2004-08-19 2007-04-25 알자 코포레이션 제어 방출형 나노입자 활성제 제제 제형 및 방법
AU2006231967B2 (en) * 2005-03-31 2011-09-15 Suntory Holdings Limited Oil-in-water emulsions containing lignan-class compounds and compositions containing the same
KR100682531B1 (ko) 2005-04-06 2007-02-15 유효경 양쪽성 계면활성제와 폴리올을 함유하는 가용화용나노조성물
EP1933811A2 (en) * 2005-09-30 2008-06-25 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
KR20090045205A (ko) * 2006-06-26 2009-05-07 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 활성제 제형 및 이의 제조방법 및 사용방법
AU2007305614B2 (en) * 2006-10-04 2012-08-23 Suntory Holdings Limited O/W/O emulsion containing lignan compounds and composition containing the same
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
IT1393245B1 (it) * 2008-07-24 2012-04-12 Universita' Degli Studi Di Milano Forme farmaceutiche per il rilascio tempo-specifico di farmaci
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9431262B2 (en) 2014-03-14 2016-08-30 Fujikoshi Machinery Corp. Method for polishing work and work polishing apparatus
WO2016071756A1 (en) * 2014-11-04 2016-05-12 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
GB2541387A (en) * 2015-08-14 2017-02-22 Res Center Pharmaceutical Eng Gmbh Self-emulsifying Nanosuspensions as Drug Delivery Systems (SENDDS)
PL428779A1 (pl) * 2019-01-31 2020-08-10 Gdański Uniwersytet Medyczny Kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534280A (en) * 1895-02-19 Hose-leak stop or jacket
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5578642A (en) * 1994-08-17 1996-11-26 Henkel Corporation Self-emulsifying and/or emollient agents
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
UA68350C2 (en) * 1997-07-01 2004-08-16 Pfizer Prod Inc Dosage forms of encapsulated sertraline
CA2313024C (en) * 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6183466B1 (en) * 1998-08-21 2001-02-06 Alza Corporation Dosage form comprising a capsule
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6221391B1 (en) * 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
EP1135150B1 (en) * 1998-12-11 2012-10-17 Tris Pharma, Inc. Self-emulsifying compositions for drugs poorly soluble in water
HUP0104721A3 (en) * 1998-12-17 2006-07-28 Alza Corp Mountain View Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
DE60109295T2 (de) * 2000-07-24 2006-04-13 Sugen, Inc., South San Francisco Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
CA2422580C (en) * 2000-09-18 2011-05-17 Rpg Life Sciences Limited Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities
EP1458353A1 (en) * 2001-12-19 2004-09-22 ALZA Corporation Formulation dosage form for the controlled delivery of ther apeutic agents

Also Published As

Publication number Publication date
US20040142040A1 (en) 2004-07-22
KR20050083875A (ko) 2005-08-26
UY28057A1 (es) 2003-12-31
TW200423968A (en) 2004-11-16
AU2003291667A1 (en) 2004-06-07
EP1556000A1 (en) 2005-07-27
WO2004041246A1 (en) 2004-05-21
JP2006507309A (ja) 2006-03-02
CA2504031A1 (en) 2004-05-21
CN1728982A (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
AR041745A1 (es) Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos
CY1126112T1 (el) Φαρμακοτεχνικες μορφες που περιεχουν ενυδρη προπυλενογλυκολη δαπαγλιφλοζινης
CY2017014I1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
DK1411900T3 (da) Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
DE69920689D1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
FR2930140B1 (fr) Dispositif pour la conservation, la preparation extemporanee et l'administration d'un faible dosage de principe actif
AR044077A1 (es) Peliculas consumibles por via oral que se disuelven rapidamente, que contienen un edulcorante
SV2007002120A (es) Dispositivo inhalador de medicamentos
CY1106727T1 (el) Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων
JP2010503695A5 (es)
UY27627A1 (es) Aza - arilpiperazinas
CY1117480T1 (el) Χρηση ενωσεων εστερα υδροξυβενζοϊκου οξεος για την κατασκευη ενος φαρμακου για την προληψη και θεραπευτικη αγωγη λοιμωξης απο hpv
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
RU2008107596A (ru) Композиции частиц, включающие альгинат и/или альгиновую кислоту
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
NO20024194D0 (no) Nytt selvemulgerende legemiddelavleveringssystem
ATE366105T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
ATE395043T1 (de) Amoxycillin und clavulanat enthaltende pharmazeutische brausefromulierung
CY1106964T1 (el) Φαρμακα που περιεχουν ν,ν’-διυποκατεστημενες ενωσεις πιπεραζινης και η χρησιμοποιηση τους

Legal Events

Date Code Title Description
FA Abandonment or withdrawal